These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32633605)

  • 21. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients.
    Wawrzyniak S; Koziarska D; Kułakowska A; Bartosik-Psujek H; Adamczyk-Sowa M
    Neurol Neurochir Pol; 2019; 53(2):131-137. PubMed ID: 30855704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
    Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
    Ouallet JC
    Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
    Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Baroncini D; Zaffaroni M; Moiola L; Lorefice L; Fenu G; Iaffaldano P; Simone M; Fanelli F; Patti F; D'Amico E; Capobianco M; Bertolotto A; Gallo P; Margoni M; Miante S; Milani N; Amato MP; Righini I; Bellantonio P; Scandellari C; Costantino G; Scarpini E; Bergamaschi R; Mallucci G; Comi G; Ghezzi A
    Mult Scler; 2019 Mar; 25(3):399-407. PubMed ID: 29363396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease modifying therapies for relapsing multiple sclerosis.
    Wingerchuk DM; Weinshenker BG
    BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
    Lanzillo R; Bonavita S; Quarantelli M; Vacca G; Lus G; Amato L; Carotenuto A; Tedeschi G; Orefice G; Brescia Morra V
    Neurol Sci; 2013 Apr; 34(4):521-8. PubMed ID: 22526763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
    Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
    Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
    Capobianco M; Bertolotto A; Malucchi S
    Neurol Sci; 2021 May; 42(Suppl 1):25-28. PubMed ID: 33712907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.